CPHI logo

CHINA PHARMA HOLDINGS INC

CPHINYSE AMERICAN
๐Ÿ† #3626 by market capUS Equity
$1.11โ–ฒ $0.00 (+0.00%)
Market closed ยท at close
1hโ€”
24hโ–ฒ 0.0%
7dโ–ผ 9.8%
14dโ–ผ 4.7%
30dโ–ฒ 84.2%
1yโ–ผ 20.4%
๐ŸฆMarket Cap
$45M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
-8.5%
Declining
๐Ÿ“ŠGross Margin
-13.4%
Thin
๐Ÿ’ตFCF Margin
3.4%
Moderate
โš–๏ธP/S Ratio
11.5x
Elevated
Otter Score
44
Weak

Trading Snapshot

Day Range
$1.10 โ€“ $1.12
52-Week Range
$0.38 โ€“ $19.19
Volume
$1.81B
Avg Volume
$2.25B
Shares Outstanding
40.5M
Next Earnings
Sep 24, 2026

Fundamentals Snapshot

Annual Revenue
$4M
Last Q Revenue
$983,536
P/E Ratio
-1.4
P/S Ratio
11.5x
EPS (TTM)
$-0.83
Dividend Yield
0.00%

Why Investors Own CPHI

  • โœ“High-growth profile โ€” revenue up +45.0% YoY with expanding US Equity exposure.
  • โœ“Healthy economics โ€” 71% gross margin and 26% free-cash-flow margin.
  • โœ“New products and segments could unlock additional revenue streams.
โš ๏ธ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$4Mโ–ฒ +38.7% YoY
Gross Margin (TTM)
71.1%โ–ฒ +1.8% YoY
Operating Income (TTM)
$1Mโ–ฒ +38.7% YoY
Free Cash Flow (TTM)
$1Mโ–ฒ +38.7% YoY

About CHINA PHARMA HOLDINGS INC

China Pharma Holdings, Inc. (CPHI) specializes in the development, manufacturing, and marketing of both generic and branded pharmaceutical as well as biochemical products. The company primarily caters to hospitals and independent retailers throughout mainland China. Its comprehensive product portfolio encompasses diverse formulations, including powdered and liquid injectables, oral tablets, capsules, and cephalosporin-based oral solutions. CPHI's extensive range of medical solutions targets various health conditions. For neurological and cognitive health, it offers Cerebroprotein Hydrolysate injections to address memory decline and attention deficits, and Gastrodin injections for symptoms such as fatigue, lack of concentration, sleep disturbances, and traumatic brain syndromes. Cardiovascular and cerebrovascular treatments include Propylgallate and Ozagrel Sodium for conditions like cerebral thrombosis, coronary heart disease, and post-surgical recovery, as well as Alginic Sodium Diester injections targeting ischemic heart disease, cerebrovascular ailments, and hyperlipoproteinemia. Additionally, CPHI provides Bumetanide injections for edema management and Candesartan for hypertension. The company also produces a variety of anti-infective medications. These feature Roxithromycin dispersible tablets for throat infections (pharyngitis and tonsillitis), and Cefaclor dispersible tablets effective against conditions such as otitis media, lower respiratory tract infections, urinary tract infections, and skin/soft tissue infections. Other anti-infectives include Cefalexin capsules for acute tonsillitis, Andrographolide for sore throats stemming from upper respiratory tract infections, and Clarithromycin available in both granule and capsule forms. For pain and cold relief, CPHI offers sustained-release tablets containing Naproxen Sodium and Pseudoephedrine Hydrochloride. Furthermore, CPHI manufactures treatments for digestive disorders, including Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeprazole. The product lineup extends to Vitamin B6 injections, Granisetron Hydrochloride injections for alleviating nausea and vomiting induced by cancer therapies (radiotherapy and chemotherapy), and dietary supplements like Noni Enzyme. Complementing its medical offerings, the company also provides health-related products such as sanitizers and protective masks. The company distributes its offerings via a network of third-party distributors, augmented by its own 16 sales offices and a team of around 1,000 sales professionals. Established in 1993, China Pharma Holdings, Inc. maintains its headquarters in Haikou, located in the People's Republic of China.

๐Ÿฆฆ

Otter Score Breakdown

โ“˜
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Weak
44/100

Analyst Price Target

โ“˜
Average Target
$1.13
โ–ฒ +2.0% Upside
High Target$1.26
Low Target$0.85
Based on 18 analysts

Latest News & Updates

ChartMillยท20d ago

Top movers analysis one hour before the close of the markets on 2026-07-22: top gainers and losers in today's session.

Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Benzingaยท20d ago

12 Health Care Stocks Moving In Wednesday's After-Market Session

Gainers Zhengye Biotechnology (NASDAQ:ZYBT) shares moved upwards by 24.0% to $1.71 during Wednesday's after-market session. The market value of their outstanding shares is at $135.0 million. Medpace Holdings

ChartMillยท20d ago

These stocks have an unusual volume in today's session

Unusual volume stocks in Wednesday's session

ChartMillยท20d ago

Top movers analysis in the middle of the day on 2026-07-22: top gainers and losers in today's session.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

ChartMillยท20d ago

Gapping stocks in Wednesday's session

The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Benzingaยท20d ago

12 Health Care Stocks Moving In Wednesday's Intraday Session

Gainers Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 108.6% to $14.77 during Wednesday's regular session. The company's market cap stands at $11.5 million. Lakewood-Amedex (NASDAQ:LABT) shares moved